Tc-99m MIBI localization in bone marrow: A marker of bone marrow malignancy

Clinical Nuclear Medicine

Volumn 23, Issue 10, 1998, Pages 664-671

  Wakasugi, Shigetoshi ^a   Teshima, Hirofumi ^a   Nakamura, Hiroyuki ^a   Hashizume, Terumi ^a   Maeda, Tetsuo ^a,b   Hiraoka, Akira ^a   Hasegawa, Yoshihisa ^a   Masaoka, Tohru ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Bone Marrow Malignancy; Bone Scan; MRI; Tc 99m MIBI

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TUMOR MARKER;

ADULT; ARTICLE; BONE MARROW CANCER; BONE MARROW CELL; BONE METASTASIS; BONE SCINTISCANNING; DIAGNOSTIC IMAGING; FEMALE; GRANULOCYTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHAGOCYTOSIS; REMISSION; TUMOR LOCALIZATION;

ADULT; AGED; BONE MARROW; BONE MARROW NEOPLASMS; BONE NEOPLASMS; FEMALE; HUMANS; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMACYTOMA; PROSPECTIVE STUDIES; TECHNETIUM TC 99M SESTAMIBI;

EID: 0031766219     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-199810000-00004     Document Type: Article

References (29)

1. Munz DL, Sandrock D, Rillinger N, et al: Comparison of immunoscintigraphy and colloid scintigraphy of bone marrow Letter. Lancet I:258, 1990.
2. Reske SN: Recent advances in bone marrow scanning. Eur J Nucl Med 18:203, 1991.
3. Haubold-Reuter BG, Duewell S, Schilcher BR, et al: The value of bone scintigraphy, bone marrow scintigraphy, and fast spinecho magnetic resonance imaging in staging of patients with malignant solid tumors: A prospective study. Eur J Nucl Med 20:1063, 1993.
4. Jones AG, Abrams MJ, Davison A, et al: Biological studies on a new class of technetium complexes: The hexakis (alkylisonitrile) technetium (I) cation. Int J Nucl Med Biol 11:225, 1984.
5. Gerundini P, Savi A, Gilardi MC: Evaluation in dogs and humans of three potential technetium-99m myocardial perfusion agents. J Nucl Med 27:409, 1986.
6. Mu̧ller ST, Guth-Tougelides B, Creutzig H: Imaging of malignant tumors with Tc-99m MIBI SPECT (Abstract). J Nucl Med 30:845, 1987.
7. Hassan IM, Sahweil A, Constantinides C, et al: Uptake and kinetics of Tc-99m hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs. Clin Nucl Med 14:333, 1989.
8. O'Tuama L, Packard A, Treves S, et al: SPECT imaging of pediatric brain tumor with hexakis (methoxyisobutylisonitrile) technetium (1). J Nucl Med 31:2040, 1990.
9. Coakley AJ, Kettle AG, Wells CP, et al: Technetium-99m sestamibi - a new agent for parathyroid imaging. Nucl Med Commun 10:791, 1989.
10. Aktolun C, Bayhan H, Kir M, et al: Clinical experience with Tc-99m MIBI imaging in patients with malignant tumors preliminary results and comparison with TI-201. Clin Nucl Med 17:171, 1992.
11. Campeau RJ, Kronemer KA, Sutherland CM, et al: Concordant uptake of Tc-99m sestamibi and TI-201 in unsuspected breast tumor. Clin Nucl Med 17:936, 1992.
12. Waxman AD, Ashok G, Kooba A, et al: The use of Tc-99m primary carcinoma of the breast: Comparison with TI-201 (TI) methoxyisobutyl isonitrile (MIBI) in evaluation of patients with (Abstract). J Nucl Med 34(suppl):140, 1993.
13. Khalkhali I, Mena I, Jouanne E, et al: Technetium-99m sestaMIBI prone breast imaging in patients with suspicion of breast cancer (Abstract). J Nucl Med 34 (suppl):140, 1993.
14. Caner B, Kitapcl M, Unlu M, et al: Technetium-99m MIBI uptake in benign and malignant bone lesions: A comparative study with technetium-99m MDP. J Nucl Med 33:319, 1992.
15. Jonsson C, Jacobsson H, et al: Accumulation of Tc-99m MIBI in bone marrow. Ann Nucl Med 3:281, 1996.
16. Vogler JB, Murphy WA: Bone marrow imaging. Radiology 168: 679, 1988.
17. Moulopoulos LA, Dimopoulos M: Magnetic resonance imaging of the bone marrow in hematologic malignancies. Blood 90:2127, 1997.
18. Pan G, Raymond AK, Carraco H: Osteosarcoma: MR imaging after preoperative chemotherapy. Radiology 174:517, 1990.
19. Holsher HC, Bloem JL, Nooy MA, et al: The value of MR imaging in monitoring the effect of chemotherapy on bone sarcomas. AJR 154:763, 1990.
20. Hanna SL, Fletcher BD, Fairclough DL, et al: Magnetic resonance imaging of disseminated bone marrow disease in patients treated for malignancy. Skeletal Radiol 20:79, 1991.
21. Lewis S, Wainscoat JS, Moore NR, et al: Magnetic resonance imaging in myelodysplastic syndromes. Br J Radiol 68:121, 1995.
22. Vande Berg BC, Schmitz PJ, Scheiff JM, et al: Acute myeloid leukemia: Lack of predictive value of sequential quantitative MR imaging during treatment. Radiology 197:301, 1995.
23. Vande Berg BC, Michaux L, Scheiff JM, et al: Sequential quantitative MR analysis of bone marrow: Differences during treatment of lymphoid versus myeloid leukemia. Radiology 201:519, 1996.
24. Chiu M, Kronauge JF, Piwnica-Worms D, et al: Effect of mitochondrial and plasma-membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium (I) in cultured mouse fibroblasts. J Nucl Med 31:1646, 1990.
25. Maublant JC, Zhang Z, Rapp M, et al: In vitro uptake of technetium-99m teboroxime in carcinoma cell lines and normal cells: Comparison with technetium-99m sestamibi and thallium-201. J Nucl Med 34:1949, 1993.
26. Delmon-Moingeon LI, Piwnica-Worms D, Van-den-Abbeele AD, et al: Uptake of the cation hexakis (2-methoxyisobutylisonitrile) technetium-99m by human carcinoma cell lines in vitro. Cancer Res 50:2198, 1990.
27. Hoane BR, Shields AF, Porter BA, et al: Detection of lymphomatous bone involvement with magnetic resonance imaging. Blood 78:728, 1991.
28. Kricum ME: Red-yellow marrow conversion: Its effect on the location of some solitary bone lesions. Skeletal Radiol 14:10, 1985.
29. Takagi S, Tanaka O, Miura Y, et al: Magnetic resonance imaging of femoral marrow in patients with myelodysplastic syndromes or leukemia. Blood 86:316, 1995.